Key Quantitative Figures
Consolidated Financial Results (₹ crore)
- Total Income: ₹2,035.49 (Q1 FY27) vs ₹1,123.37 (Q1 FY26) vs ₹1,580.00 (Q4 FY26)
- Profit Before Tax: ₹481.36 (Q1 FY27) vs ₹361.37 (Q1 FY26) vs ₹224.22 (Q4 FY26)
- Net Profit After Tax: ₹362.07 (Q1 FY27) vs ₹282.09 (Q1 FY26) vs ₹161.68 (Q4 FY26)
- EPS (Basic): ₹6.81 (Q1 FY27) vs ₹5.17 (Q1 FY26) vs ₹3.02 (Q4 FY26)
- EPS (Diluted): ₹6.80 (Q1 FY27) vs ₹5.17 (Q1 FY26) vs ₹3.02 (Q4 FY26)
Standalone Financial Results (₹ crore)
- Revenue from Operations: ₹1,757.16 (Q1 FY27) vs ₹1,580.30 (Q1 FY26) vs ₹1,432.75 (Q4 FY26)
- Profit Before Tax: ₹388.17 (Q1 FY27) vs ₹259.37 (Q1 FY26) vs ₹211.44 (Q4 FY26)
- Net Profit After Tax: ₹289.96 (Q1 FY27) vs ₹191.79 (Q1 FY26) vs ₹157.94 (Q4 FY26)
- EPS (Basic): ₹5.37 (Q1 FY27) vs ₹3.55 (Q1 FY26) vs ₹2.93 (Q4 FY26)
- EPS (Diluted): ₹5.36 (Q1 FY27) vs ₹3.55 (Q1 FY26) vs ₹2.93 (Q4 FY26)
Dates of Action
- Board Meeting: July 24, 2026 (2:00 PM IST to 2:42 PM IST)
- Quarter Ended: June 30, 2026
- Filing Date: July 24, 2026
Parties Involved
- Statutory Auditors: Deloitte Haskins & Sells LLP
- Subsidiaries: Sriam Labs Private Limited, Laurus Holdings Limited, Laurus Generics Inc, Laurus Generics GmbH, Laurus Synthesis Private Limited, Laurus Generics SA (Pty) Ltd, Laurus Bio Private Limited (78.34%), Laurus Specialty Chemicals Private Limited
- Associates: Immunoadoptive Cell Therapy Private Limited (34.89%), Ethan Energy India Private Limited (26.00%)
- Joint Venture: KRKA Pharma Private Limited (49.00%)
Capital Structure Impact
- Paid-up Equity Share Capital: ₹108.05 crore (face value ₹2 each)
- During Q1 FY27, company allotted 393,001 equity shares of ₹2 each consequent to exercise of stock options by employees under Employee Stock Option Scheme
Corporate Development
Composite Scheme of Arrangement approved by Board on August 21, 2025 for:
- Demerger of Identified Business Undertaking of Laurus Synthesis Private Limited into Sriam Labs Private Limited
- Amalgamation of Remaining Undertaking of Laurus Synthesis Private Limited with Laurus Labs Limited
- Appointed Date: April 01, 2026 (subject to NCLT approval)
- Scheme filed with National Company Law Tribunal, Amaravati Bench
- Financial results presented without giving effect to the said merger pending final approvals
Auditor's Review Scope
- Deloitte Haskins & Sells LLP issued unmodified conclusion for limited review
- Did not review interim financial information of six subsidiaries reflecting total revenues of ₹177.14 crores and net loss of ₹5.96 crores for Q1 FY27
- Did not review interim financial information of one joint venture (KRKA Pharma) with share of profit after tax of ₹0.14 crores
- Relied on management-certified interim financial information for one associate with share of profit after tax of ₹0.16 crores
Additional Notes
- Figures for quarter ended March 31, 2026 are balancing figures between audited full year and published YTD figures up to Q3 FY26
- Group engaged in single reportable business segment of "Pharmaceuticals" as per Ind AS 108